

Corrigendum: Design of a genome-wide siRNA library using an artificial neural network

Dieter Huesken, Joerg Lange, Craig Mickanin, Jan Weiler, Fred Asselbergs, Justin Warner, Brian Meloon, Sharron Engel, Avi Rosenberg, Dalia Cohen, Mark Labow, Mischa Reinhardt, François Natt & Jonathan Hall

Nat. Biotechnol. 23, 995–1001 (2005)

On page 1,000, in the last Methods section, line 4 from bottom of page, “HeLa cells were treated with 100 mM Deferoxamine Mesylate” should have read “HeLa cells were treated with 100 μ M Deferoxamine Mesylate.”

In the supplementary online information, the original **Supplementary Table 3** erroneously showed the Biopred algorithm scores (predicted relative activity) in the last column, instead of experimentally determined ‘Normalized inhibitory activity’. This has been corrected in the new **Supplementary Table 3** and the appropriate footnotes added. The changes affect all of the \sim 3,000 values listed in the last column of the table.

Corrigendum: Overexpression of an *Arabidopsis thaliana* ABC transporter confers kanamycin resistance to transgenic plants

Ayalew Mentewab & C Neal Stewart Jr

Nat. Biotechnol. 23, 1177–1180 (2005)

On p. 1180, line 4, the reverse primer to amplify the gene encoding Atwbc19 was given as (5'-TGTCCTCGTTTTATCCAAG-3'). The reverse primer used was 5'-GTCAGCGAGCTCTCACGTCCTCTTATTCCTGC-3', which contains a *SacI* site.

Erratum: Chasing a cellular fountain of youth

Ken Howard Wilan, Christopher Thomas Scott & Stephan Herrera

Nat. Biotechnol. 23, 807–815 (2005)

On page 808, in **Table 1**, the entry for MacroPore Biosurgery (which since the publication of this article has changed its name to Cytori Therapeutics) erroneously listed “liver-assist device (with subsidiary Xenogenics)” after “Cell-based therapies, bioresorbable therapies” in the business model column. It should have read simply, “Cell-based therapies, bioresorbable therapies.”